Accendra Health, Inc.
Accendra Health, Inc. is classed by the SEC under Wholesale-Medical, Dental & Hospital Equipment & Supplies (industry code 5047), based in Glen Allen, VA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $2.8 billion and a loss of $1.1 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a distribution business: prior from its industry code (SEC 5047, Wholesale-Medical, Dental & Hospital Equipment & Supplies); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.0 out of ten, 9 of 9 metrics filed: past 1.8 out of ten, present 3.1 out of ten, future 3.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 0.9 out of ten. 3 warning events since 2017; the latest 2026-10-09. 9th percentile among 51 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 1.9 out of ten. -13.1% a year over 10 filed years; profitable in 5 of 10. 19th percentile among 50 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 3.4 out of ten. Share count grew 0.3% a year. 1% of cash flow returned. Insiders: 0 sales, 0 purchases. 34th percentile among 43 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 4.7 out of ten. Leverage 119%: owes 119¢ per asset dollar. 47th percentile among 50 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 2.6 out of ten. bottom 26% of 51 in its family; net margin -39.8%. 26th percentile among 51 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 1.8 out of ten. bottom 18% of 35 in its family for leadership; chief executive since 2026. 18th percentile among 35 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.0 out of ten. bottom 40% of 49 in its family for room to expand. 40th percentile among 49 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 3.5 out of ten. bottom 35% of 50 in its family for growth drivers. 35th percentile among 50 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 3.6 out of ten. bottom 36% of 44 in its family for expectations against reality. 36th percentile among 44 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-20 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-10 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-10 (on EDGAR). Newest filing: Form 8-K, 2026-10-09. Filings on record since 1994. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Diabetes Product 28%, Sleep Therapy Product 27%, Home Respiratory Therapy Product 16%, Product and Service Other 10%, Ostomy 8%, Wound Care 7%. As tagged in its annual report (Form 10-K, filed 2026-02-20).
Who runs it
Gardner-Smith, Kenneth (President & CEO); Pesicka, Edward A (President & CEO); Long, Andrew G (EVP, CEO P&HS); Leon, Jonathan A (EVP & CFO); Bernocchi, Perry A (EVP, Chief Operating Officer); Galloway, Heath H (EVP,General Counsel & CorpSecy); Beck, Mark A (director); Bingham, Gwendolyn M (director); Klemash, Stephen W (director); Kline, Teresa L. (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-06.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.